YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Income / Options OverlaySector
- $46.7152W High
- $36.5752W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF has traded between a low of $36.57 and a high of $46.71, highlighting its annual price range. Buy and sell YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Most Recent News
US private employers added 12,000 jobs weekly on average in August, showing hiring acceleration.
For the four weeks ending August 22, 2026, US private employers added an average of 12,000 jobs per week, according to ADP's National Employment Report Pulse. This figure shows an acceleration in hiring compared to previous weeks, reflecting a positi...

Five top dividend stocks trade near 52-week lows, offering high yields for patient investors.
Five well-known dividend-paying companies—Clorox, Comcast, Duke Energy, General Mills, and VICI Properties—are currently trading near their 52-week lows, presenting attractive opportunities for income-focused investors. These stocks offer high divide...

Inhibrx advances cancer drugs with FDA review for ozekibart due by April 2027
Inhibrx is progressing its cancer treatments ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets. Ozekibart showed a 52% risk reduction in chondrosarcoma progression and strong responses in colorectal and Ewing sarcoma, ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.